Drs. Bradley Monk and Robert Coleman examine practical issues to consider in managing toxicities associated with antiangiogenic agents: dealing with side effects of first-line versus palliative treatment, the possibility of dose reduction to alleviate toxicities, risk factors for catastrophic side e…
The experts discuss the current and future practical uses of tumor sensitivity assays and molecular profiling.
The experts discuss the management of bevacizumab toxicities in first-line vs palliative treatment and the need to monitor for serious side effects.